西黄胶囊对肝癌术后放化疗不良反应的影响
|
摘要
目的:探讨西黄胶囊对肝癌术后放化疗不良反应的影响。方法:纳入126例肝癌患者作为研究对象,按照随机数字表法将其分为观察组和对照组各63例,对照组患者术后接受常规放化疗治疗,观察组在此基础上加服西黄胶囊治疗,疗程均为6个周期,比较2组近期疗效,并分析西黄胶囊对胃肠道反应、丙氨酸转氨酶升高、骨髓抑制及血液系统不良反应等的影响。结果:观察组近期疗效总有效率为76.19%,对照组为71.43%,2组比较,差异无统计学意义(χ~2=0.370,P> 0.05)。与对照组比较,观察组胃肠道反应持续时间较短,血液系统不良反应较少,差异均有统计学意义(P <0.05)。2组丙氨酸转氨酶升高比例及骨髓抑制比较,差异无统计学意义(P> 0.05)。结论:西黄胶囊可减轻肝癌患者术后放疗及部分化疗不良反应。
Objective: To explore the effect of Xihuang capsules on the postoperative side effects of radiotherapy and chemotherapy for liver cancer. Methods:Enrolled 126 cases of patients with liver cancer in this study,and divided them into the observation group and the control group according to random number table,respectively,63 cases in each group. The control group received routine radiotherapy and chemotherapy, while the observation group was additionally treated with Xihuang capsules. The course of the treatment was 6 cycles. Compared the short-term effects in the two groups, and analyzed the effects of Xihuang capsules on toxic and side effects such as gastrointestinal side effects,alanine aminotransferase elevation,bone marrow suppression and blood system side effects. Results:The total effective rate of the short-term effect was 76.19% in the observation group and 71.43% in the control group,compared the two groups,no significant difference being found between the two groups(χ~2=0.370, P > 0.05). Compared with that in the control group, the gastrointestinal reaction duration in the observation group was shorter, and the toxic and side effects of the blood system were less,differences being significant(P < 0.05). There was no significant difference being found in the comparison of the ratio of alanine aminotransferase and bone marrow suppression between the two groups(P > 0.05). Conclusion: The application of Xihuang capsules can alleviate postoperative side effects of radiotherapy and partial chemotherapy in patients with liver cancer.
Objective: To explore the effect of Xihuang capsules on the postoperative side effects of radiotherapy and chemotherapy for liver cancer. Methods:Enrolled 126 cases of patients with liver cancer in this study,and divided them into the observation group and the control group according to random number table,respectively,63 cases in each group. The control group received routine radiotherapy and chemotherapy, while the observation group was additionally treated with Xihuang capsules. The course of the treatment was 6 cycles. Compared the short-term effects in the two groups, and analyzed the effects of Xihuang capsules on toxic and side effects such as gastrointestinal side effects,alanine aminotransferase elevation,bone marrow suppression and blood system side effects. Results:The total effective rate of the short-term effect was 76.19% in the observation group and 71.43% in the control group,compared the two groups,no significant difference being found between the two groups(χ~2=0.370, P > 0.05). Compared with that in the control group, the gastrointestinal reaction duration in the observation group was shorter, and the toxic and side effects of the blood system were less,differences being significant(P < 0.05). There was no significant difference being found in the comparison of the ratio of alanine aminotransferase and bone marrow suppression between the two groups(P > 0.05). Conclusion: The application of Xihuang capsules can alleviate postoperative side effects of radiotherapy and partial chemotherapy in patients with liver cancer.
引文
[1]中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范(2017年版)[J].传染病信息,2017,16(7):705-720.
[2]梁宏元,卢再鸣.原发性肝癌综合介入治疗现状与困惑[J].临床肝胆病杂志,2016,32(1):44-48.
[3]杨强,王翔,马胜辉,等.单纯奥沙利铂-替吉奥化疗方案与化疗辅助西黄胶囊治疗晚期胃癌的疗效及对T细胞亚群、生存率及不良反应的影响[J].实用临床医药杂志,2017,29(17):51-54.
[4]张晓玲,邢荣格,苗志刚,等.西黄胶囊辅助化疗治疗结肠癌术后肝转移疗效及对患者外周血IL-17和IL-6的影响[J].中草药,2015,46(6):871-874.
[5]王黎.西黄胶囊联合化疗治疗中晚期乳腺癌的疗效观察[J].中医药学报,2015,17(6):82-84.
[6] U.S.Department of Health and Human Services,National Institutes of Health,National Cancer Institute.Common terminology criteria for adverse events(CTCAE)version 4.0[Z/OL].2009:214.https://ctep.cancer.gov/protocol Development/electronic-applications/ctc.htm ctc-40.
[7]孙燕,石远凯.临床肿瘤内科手册[M].6版.北京:人民卫生出版社,2015:136.
[8]王黎君,殷鹏,刘韫宁,等.1990年与2013年中国人群肝癌疾病负担研究[J].中华流行病学杂志,2016,37(6):758-762.
[9]占义平,凌昌全.原发性肝癌中医证候研究概述[J].中医杂志,2017,58(2):166-169.
[10]封小强.中西医结合用于治疗肝癌患者肝功能的量变指标观察[J].中西医结合心血管病电子杂志,2016,35(4):170.
[11]张长永,闫雷,李红.西黄胶囊减轻肺癌化疗不良反应的临床效果观察[J].广西医学,2016,38(5):664-666.
[12]周璇,廖盼丽,吴文英,等.西黄胶囊联合GP方案对中晚期乳腺癌患者血清TNF-α,VEGF,MMP-2,MMP-9水平的影响[J].现代生物医学进展, 2017, 17(23):4525-4528.
[13]邱刚,刘苗苗,房保栓,等.西黄胶囊联合图像引导放射治疗中晚期宫颈癌疗效观察[J].现代中西医结合杂志,2017,26(27):3007-3009.
[2]梁宏元,卢再鸣.原发性肝癌综合介入治疗现状与困惑[J].临床肝胆病杂志,2016,32(1):44-48.
[3]杨强,王翔,马胜辉,等.单纯奥沙利铂-替吉奥化疗方案与化疗辅助西黄胶囊治疗晚期胃癌的疗效及对T细胞亚群、生存率及不良反应的影响[J].实用临床医药杂志,2017,29(17):51-54.
[4]张晓玲,邢荣格,苗志刚,等.西黄胶囊辅助化疗治疗结肠癌术后肝转移疗效及对患者外周血IL-17和IL-6的影响[J].中草药,2015,46(6):871-874.
[5]王黎.西黄胶囊联合化疗治疗中晚期乳腺癌的疗效观察[J].中医药学报,2015,17(6):82-84.
[6] U.S.Department of Health and Human Services,National Institutes of Health,National Cancer Institute.Common terminology criteria for adverse events(CTCAE)version 4.0[Z/OL].2009:214.https://ctep.cancer.gov/protocol Development/electronic-applications/ctc.htm ctc-40.
[7]孙燕,石远凯.临床肿瘤内科手册[M].6版.北京:人民卫生出版社,2015:136.
[8]王黎君,殷鹏,刘韫宁,等.1990年与2013年中国人群肝癌疾病负担研究[J].中华流行病学杂志,2016,37(6):758-762.
[9]占义平,凌昌全.原发性肝癌中医证候研究概述[J].中医杂志,2017,58(2):166-169.
[10]封小强.中西医结合用于治疗肝癌患者肝功能的量变指标观察[J].中西医结合心血管病电子杂志,2016,35(4):170.
[11]张长永,闫雷,李红.西黄胶囊减轻肺癌化疗不良反应的临床效果观察[J].广西医学,2016,38(5):664-666.
[12]周璇,廖盼丽,吴文英,等.西黄胶囊联合GP方案对中晚期乳腺癌患者血清TNF-α,VEGF,MMP-2,MMP-9水平的影响[J].现代生物医学进展, 2017, 17(23):4525-4528.
[13]邱刚,刘苗苗,房保栓,等.西黄胶囊联合图像引导放射治疗中晚期宫颈癌疗效观察[J].现代中西医结合杂志,2017,26(27):3007-3009.